Total pharma industry M&A deals in Q1 2019 worth $136.23bn were announced globally, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 42.8% over the previous quarter and a rise of 179.9% when compared with the last four-quarter average, which stood at $48.67bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $129.19bn. At the country level, the US topped the list in terms of deal value at $127.86bn.
In terms of volumes, North America emerged as the top region for pharma industry M&A deals globally, followed by Europe and then Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe top country in terms of M&A deals activity in Q1 2019 was the US with 54 deals, followed by China with nine and Germany with seven.
In 2019, as of the end of Q1 2019, pharma M&A deals worth $136.23bn were announced globally, marking an increase of 134.3% year on year.
Pharma industry M&A deals in Q1 2019: Top deals
The top five pharma industry M&A deals accounted for 91.9% of the overall value during Q1 2019.
The combined value of the top five pharma industry M&A deals stood at $125.17bn, against the overall value of $136.23bn recorded for the quarter. The top announced pharma industry M&A deal tracked by GlobalData in Q1 2019 was Bristol-Myers Squibb‘s $89.54bn acquisition of Celgene.
In second place was the $21.4bn asset transaction with General Electric by Danaher and in third place was Eli Lilly’s $8bn acquisition of Loxo Oncology.
The $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and Grifols‘ stake acquisition of Shanghai RAAS Blood Products for $1.93bn held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
